See What HealthDay Can Do For You
Contact Us

ACOG: Flibanserin Effective for Sexual Desire Disorder

Medication group significantly more likely than placebo group to report improvement

TUESDAY, May 18 (HealthDay News) -- In premenopausal women with generalized acquired hypoactive sexual desire disorder, the medication flibanserin appears to be an effective treatment, according to research presented this week at the annual meeting of the American College of Obstetrics and Gynecology in San Francisco.

Elaine E. Jolly, M.D., of Ottawa Hospital in Ontario, Canada, and colleagues randomly assigned 1,378 women to receive either 100 mg of flibanserin at bedtime every evening or placebo for 24 weeks. Participants rated their improvement using the seven-point Patient's Global Impression of Improvement scale, which ranges from 1 (very much improved) through four (no change) to seven (very much worse).

At the end of the study, the researchers found that a significantly higher proportion of the flibanserin group reported feeling very much improved, much improved, or minimally improved compared to the placebo group (48.3 percent versus 30.3 percent).

"A higher proportion of women who received flibanserin reported a meaningful benefit from the use of the study medication compared with those in the placebo group at study end (40.5 percent versus 25.2 percent)," the authors write.

This study was funded by Boehringer Ingelheim.

Abstract- Jolly
More Information

Physician's Briefing
undefined
undefinedundefined